Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Reporting treatment outcomes in observational data: A fine balance.
Natural history of multiple sclerosis from the Indian perspective: Experience from a tertiary care hospital.
Measuring Water Content using T2 Relaxation at 3T: Phantom Validations and Simulations.
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination.
Effect of vitamin D status on pharmacological treatment efficiency: Impact on cost-effective management in medicine.
Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-α-dependent mechanism.
Axonal selection and myelin sheath generation in the central nervous system.
Nationwide Incidence of Acquired Central Nervous System Demyelination in Icelandic Children.
Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.
Consequences of neurologic lesions assessed by Barthel Index after Botox(®) injection may be underestimated.
Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis.
Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36.
Progress in multiple sclerosis genetics.
Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation.
Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: A case report.
Targeting the low-hanging fruit of neurodegeneration.
Validity of Oxygen Uptake Efficiency Slope in patients with multiple sclerosis.
Neuropsychological rehabilitation for multiple sclerosis.
Financial Incentives, Workplace Wellness Program Participation, and Utilization of Health Care Services and Spending.
Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis.
Behavioral measurement of laser flashblindness in rhesus monkeys.
Validity of visual perceptive computing for static posturography in patients with multiple sclerosis.
Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis.
The immunomodulatory oligodendrocyte.
Pages
« first
‹ previous
…
519
520
521
522
523
524
525
526
527
…
next ›
last »